Table 2

Correlation between PCT quartiles and mortality adjusted for age and sex
Subjects Outcome Number of eventsa Q2 versus Q1 Q3 versus Q1 Q4 versus Q1 P for linear trend
HR (95% CI) HR (95% CI) HR (95% CI)
All subjects All-cause mortality 8.39 1.05 (0.77 to 1.43) 1.29 (0.96 to 1.73) 1.63 (1.22 –to 2.17) <0.001***
Cancer mortality 3.88 1.07 (0.69 to 1.68) 1.47 (0.96 to 1.25) 1.60 (1.04 to 2.43) 0.014*
CVD mortality 2.34 1.24 (0.67 to 2.29) 1.30 (0.71 to 2.36) 1.94 (1.09 to 3.42) 0.016*
Mortality from causes other than cancer and CVD 2.16 0.92 (0.50 to 1.68) 1.08 (0.60 to 1.93) 1.49 (0.86 to 2.60) 0.096
Men All-cause mortality 11.14 0.98 (0.67 to 1.45) 0.98 (0.68 to 1.42) 1.50 (1.08 to 2.09) 0.020*
Cancer mortality 4.92 1.54 (0.86 to 2.75) 1.23 (0.68 to 2.21) 1.96 (1.15 to 3.35) 0.027*
CVD mortality 3.13 0.74 (0.34 to 1.61) 0.86 (0.43 to 1.72) 1.41 (0.76 to 2.60) 0.208
Mortality from causes other than cancer and CVD 3.09 0.65 (0.03 to 1.40) 0.86 (0.44 to 1.67) 1.15 (0.62 to 2.12) 0.557
Women All-cause mortality 6.30 1.45 (0.86 to 2.46) 1.57 (0.91 to 2.71) 2.04 (1.22 to 2.34) 0.004*
Cancer mortality 3.13 1.51 (0.77 to 2.99) 1.25 (0.59 to 2.62) 1.62 (0.81 to 3.23) 0.295
CVD mortality 1.74 1.18 (0.36 to 3.86) 1.91 (0.61 to 6.00) 2.73 (0.93 to 8.06) 0.012*
Mortality from causes other than cancer and CVD 1.46 1.66 (0.52 to 5.25) 2.17 (0.68 to 6.96) 2.40 (0.78 to 7.38) 0.106

Cox regression analysis adjusted for age and sex. aExpressed per 1,000 person years. CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; PCT, procalcitonin; Q, quartile. *P <0.05, ***P <0.001.

Cotoi et al.

Cotoi et al. BMC Medicine 2013 11:180   doi:10.1186/1741-7015-11-180

Open Data